Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants : a retrospective, single-center study
Copyright © 2024 Azari, Barkhordar, Bahri, Rad, Kamranzadeh Fumani, Mousavi, Tavakoli Shiraji, Azari, Shafaroudi and Vaezi..
Introduction: Donor choosing remains to play a pivotal role in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Numerous criteria beyond HLA compatibility impact the selection of a suitable donor.
Methods: We evaluated the effect of donor parity on transplant outcomes in a large homogeneously treated population that received an HLA-matched allo-HSCT between 2010 and 2021 at our center. All patients were transplanted from a peripheral blood stem cell source following a myeloablative Busulfan-based conditioning and an identical protocol for graftversus-host disease (GVHD) prophylaxis regimen.
Results: A total of 1103 allo-HSCT recipients were included. 188 (17.04%) had transplants from parous female donors, whereas 621 (56.30%) and 294 (26.70%) received transplants from male and nulliparous female donors, respectively. HSCTs from parous female donors compared to male and nulliparous females were associated with a significantly higher incidence of grade III-IV acute (a) GVHD (55.27% vs. 11.34 and 10.84%) and extensive chronic (c) GVHD (64.32% vs. 15.52 and 13.65%), as well as lower relapse incidence (RI).
Discussion: This study finds that while parous female donors are associated with higher incidences of grade III-IV aGVHD and extensive cGVHD post-allo-HSCT, the advantages, such as a lower RI, outweigh the risks. The results of our study provide valuable insights for donor selection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in oncology - 14(2024) vom: 08., Seite 1339605 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Azari, Mojtaba [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Donor parity |
|---|
| Anmerkungen: |
Date Revised 09.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fonc.2024.1339605 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369446658 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369446658 | ||
| 003 | DE-627 | ||
| 005 | 20240309232522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2024.1339605 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1321.xml |
| 035 | |a (DE-627)NLM369446658 | ||
| 035 | |a (NLM)38454927 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Azari, Mojtaba |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants |b a retrospective, single-center study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2024 Azari, Barkhordar, Bahri, Rad, Kamranzadeh Fumani, Mousavi, Tavakoli Shiraji, Azari, Shafaroudi and Vaezi. | ||
| 520 | |a Introduction: Donor choosing remains to play a pivotal role in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Numerous criteria beyond HLA compatibility impact the selection of a suitable donor | ||
| 520 | |a Methods: We evaluated the effect of donor parity on transplant outcomes in a large homogeneously treated population that received an HLA-matched allo-HSCT between 2010 and 2021 at our center. All patients were transplanted from a peripheral blood stem cell source following a myeloablative Busulfan-based conditioning and an identical protocol for graftversus-host disease (GVHD) prophylaxis regimen | ||
| 520 | |a Results: A total of 1103 allo-HSCT recipients were included. 188 (17.04%) had transplants from parous female donors, whereas 621 (56.30%) and 294 (26.70%) received transplants from male and nulliparous female donors, respectively. HSCTs from parous female donors compared to male and nulliparous females were associated with a significantly higher incidence of grade III-IV acute (a) GVHD (55.27% vs. 11.34 and 10.84%) and extensive chronic (c) GVHD (64.32% vs. 15.52 and 13.65%), as well as lower relapse incidence (RI) | ||
| 520 | |a Discussion: This study finds that while parous female donors are associated with higher incidences of grade III-IV aGVHD and extensive cGVHD post-allo-HSCT, the advantages, such as a lower RI, outweigh the risks. The results of our study provide valuable insights for donor selection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a donor parity | |
| 650 | 4 | |a graft-versus-host disease (GVHD) | |
| 650 | 4 | |a hematopoietic stem cell transplantation (HSCT) | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a relapse incidence | |
| 700 | 1 | |a Barkhordar, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Bahri, Tanaz |e verfasserin |4 aut | |
| 700 | 1 | |a Rad, Soroush |e verfasserin |4 aut | |
| 700 | 1 | |a Kamranzadeh Fumani, Hosein |e verfasserin |4 aut | |
| 700 | 1 | |a Mousavi, Seied Asadollah |e verfasserin |4 aut | |
| 700 | 1 | |a Tavakoli Shiraji, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Azari, Morteza |e verfasserin |4 aut | |
| 700 | 1 | |a Shafaroudi, Parisa |e verfasserin |4 aut | |
| 700 | 1 | |a Vaezi, Mohammad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 14(2024) vom: 08., Seite 1339605 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g day:08 |g pages:1339605 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2024.1339605 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |b 08 |h 1339605 | ||